

## **Antihypertensive Medication Use and Incident Breast Cancer in Women**

Elizabeth E. Devore, ScD<sup>1</sup>, Sung Kim<sup>2</sup>, Cody A. Ramin, ScM<sup>1,3</sup>, Lani R. Wegrzyn, MS<sup>4</sup>, Jennifer Massa, ScD<sup>5</sup>, Michelle D. Holmes, MD, DrPH<sup>1,4</sup>, Karin B. Michels, PhD<sup>1,4,6</sup>, Rulla M. Tamimi, ScD<sup>1,4</sup>, John P. Forman, MD<sup>7</sup>, Eva S. Schernhammer, MD, DrPH<sup>1,4,8</sup>

<sup>1</sup> Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, Massachusetts 02115

<sup>2</sup> Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115

<sup>3</sup> Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, 615 North Wolfe Street, Baltimore, Maryland 21205

<sup>4</sup> Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, Massachusetts 02115

<sup>5</sup> Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115

<sup>6</sup> Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, Massachusetts 02115

<sup>7</sup> Renal Division, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115

<sup>8</sup> Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIENNA), Bernardgasse 24/2, A-1070 Vienna, Austria

Corresponding author: Elizabeth E. Devore, 181 Longwood Avenue, Room 448, Boston, Massachusetts, 02115; phone: 617-525-2042; fax: 617-525-2008; email: [nheed@channing.harvard.edu](mailto:nheed@channing.harvard.edu)

Submitted to: Breast Cancer Research and Treatment

Online Resource 2. Relative risks of ER+ and ER- breast cancer over the follow-up period (1989-2011) in the Nurses' Health Study II, according to current use of antihypertensive medication (n=114,444)

	ER+ tumors		ER- tumors		P-heterogeneity <sup>a</sup>
	Past/never use	Current use	Past/never use	Current use	
Any antihypertensive medication					0.1
Cases/Person-years	1,735/1,765,023	404/316,122	485/1,766,110	113/316,367	
Age-adjusted RR (95% CI)	1.00 (ref)	0.90 (0.80 to 1.00)	1.00 (ref)	1.08 (0.88 to 1.34)	
Multivariable-adjusted RR (95% CI) <sup>b</sup>	1.00 (ref)	0.92 (0.82 to 1.04)	1.00 (ref)	1.05 (0.84 to 1.31)	
Diuretics					1.0
Cases/Person-years	1,999/1,973,549	139/104,200	563/1,974,789	35/104,293	
Age-adjusted RR (95% CI)	1.00 (ref)	0.87 (0.73 to 1.03)	1.00 (ref)	0.96 (0.68 to 1.36)	
Multivariable-adjusted RR (95% CI) <sup>b</sup>	1.00 (ref)	0.89 (0.75 to 1.07)	1.00 (ref)	0.93 (0.65 to 1.33)	
Beta blockers					0.2
Cases/Person-years	1,996/1,986,103	143/95,042	557/1,987,358	41/95,120	
Age-adjusted RR (95% CI)	1.00 (ref)	1.03 (0.86 to 1.22)	1.00 (ref)	1.30 (0.94 to 1.80)	
Multivariable-adjusted RR (95% CI) <sup>b</sup>	1.00 (ref)	1.05 (0.88 to 1.25)	1.00 (ref)	1.27 (0.91 to 1.76)	
Calcium channel blockers					0.3
Cases/Person-years	1,994/1,897,875	57/46,850	514/1,899,163	18/46,886	
Age-adjusted RR (95% CI)	1.00 (ref)	0.94 (0.72 to 1.22)	1.00 (ref)	1.23 (0.77 to 1.97)	
Multivariable-adjusted RR (95% CI) <sup>b</sup>	1.00 (ref)	0.96 (0.74 to 1.25)	1.00 (ref)	1.20 (0.75 to 1.93)	
ACE inhibitors					0.4
Cases/Person-years	1,961/1,859,829	90/84,896	514/1,861,092	18/84,957	
Age-adjusted RR (95% CI)	1.00 (ref)	0.80 (0.64 to 0.98)	1.00 (ref)	0.64 (0.40 to 1.02)	
Multivariable-adjusted RR (95% CI) <sup>b</sup>	1.00 (ref)	0.81 (0.66 to 1.01)	1.00 (ref)	0.62 (0.38 to 0.99)	

<sup>1</sup> P-heterogeneity calculated using the likelihood ratio test.

<sup>2</sup> These models are adjusted for age and body-mass index (<20, 20-21.9, 22-24.9, 25-29.9, ≥30 kg/m<sup>2</sup>), height (inches), oral contraceptive use (never, ever), menopausal status (premenopausal, postmenopausal), age at menopause (<45, 45-49, 50-52, ≥53 years), postmenopausal hormone use (among postmenopausal women only: never, past, current), parity and age at first birth (nulliparous, 1-2 children and <25 years old, 1-2 children and 25-29 years old, 1-2 children and ≥30 years old, ≥3 children and <25 years old, ≥3 children and ≥25 years old), age at menarche (<12, 12, 13, ≥14 years old), family history of breast cancer (yes, no), history of benign breast disease (yes, no), alcohol intake (none, 1-7.49, 7.5-14.99, 15-29.9, ≥30 grams/day), physical activity level (quintiles of MET-hours/week), smoking status (never or past, current and <25 cigarettes/day, current and ≥25 cigarettes/day), and shift work history (none, 1-9, ≥10 years).